Navigation Links
PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
Date:9/7/2010

ANNAPOLIS, Md., Sept. 7 /PRNewswire/ -- The Plasma Protein Therapeutics Association (PPTA) recommends that the Centers for Medicare and Medicaid Services (CMS) finalize its Proposed Rule regarding reimbursement to better ensure patient access to vital medicines in the hospital outpatient setting.

Specifically, for CY 2011, CMS proposes to set the payment level of separately payable non-pass-through drugs and biologicals, which include most plasma protein therapies, at average sales price (ASP) plus 6 percent. PPTA supports this proposal, believing that by setting payment rates at no less than ASP plus 6 percent, CMS will help ensure at this time that hospital outpatient departments remain a viable option for beneficiaries to receive therapies such as alpha-1 proteinase inhibitor, blood clotting factors and intravenous immune globulin (IVIG).

Furthermore, the proposed payment rate for hospital outpatient departments would put such products on par with the rates paid for pass-through drugs and biologicals in the physician office setting, thus, better assuring Medicare patients that they will have access to their necessary medications in either site of service.

"By matching payment levels in both the hospital outpatient department and the physician office, the choice of setting would be driven by clinical, not financial considerations, as it should be," said Julie Birkofer, Senior Vice President, PPTA North America.

Additionally, PPTA praised the agency's proposal to continue reimbursing hospitals for the "furnishing fee" for blood clotting factors, recommending that the proposal be made final.

While CMS' proposal makes strides with ensuring patient access to plasma protein therapies for small patient populations, PPTA continues to have concerns with the agency's flawed policy of using hospital claims data that includes drugs and biologicals sold as part of the heavily discounted 340B Drug Pricing Program when setting Outpatient
'/>"/>

SOURCE Plasma Protein Therapeutics Association (PPTA)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Clean Power Development, LLC Urges Sustainable, Community-Centric Approach to Biomass Energy
2. Tax Specialty Firm McGuire Sponsel Urges Qualifying Biotech Companies to Apply for New Qualifying Therapeutic Discovery Project Credit Soon
3. DuPont Science Leader Urges U.S. House Committee to Continue Federal Investment in Transformative, Clean Energy Technologies
4. VirtualHealth Technologies Will Change Its Name to VHGI Holdings, Inc. and Surges Forward Into Broader Market
5. Regional Biotech Association Urges Support for Biosimilars Bill in Congress
6. TechNet Urges Swift U.S. Senate Approval of FCC Nominees Julius Genachowski and Robert McDowell
7. Biotechnology Value Fund Urges Stockholders to Remove and Replace Current Board of Avigen, Inc. in an Effort to Protect and Maximize Stockholder Value
8. FCSO Selects Burgess as Exclusive Pricing Solution for New Medicare Contract
9. Beyond Turbidity: Selecting Appropriate Technology for in Situ Monitoring and Control of Complex Particle and Droplet Systems
10. Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments
11. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... MADISON, Wis. , July 28, 2014   ... chronic respiratory disease, announced the hire of Brad ... Development. Towle will be responsible for driving the company,s ... "Brad,s broad experience in healthcare, and specifically his past ... valuable insight to the company at this pivotal time ...
(Date:7/28/2014)... 2014  InterMune, Inc. (NASDAQ: ITMN ) ... 2014 financial results at the close of the U.S. ... and webcast will be hosted by InterMune at 4:30 ... investors and others may participate in the conference call ... ID#21728775. A replay of the webcast and teleconference will be ...
(Date:7/26/2014)... Canada Endoscopy Visualization Systems Market ... the Canada Endoscopy Visualization Systems market. The report ... (in units) and average prices (in US dollars) ... Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy Visualization ... . , The report also provides company shares ...
(Date:7/25/2014)... from the University of Leicester has furthered our ... potential to create new materials using nanosized ,building ... in the prestigious academic journal Physical Review ... examine in rich detail the structure and internal ... acetylene molecule and a single helium atom. , ...
Breaking Biology Technology:Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2InterMune to Release Second Quarter Financial Results on August 6 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3
... 2008 Lentigen Corporation today,announced an exclusive ... for licensing technologies from the University of,Cambridge ... area of lentiviral vector,technology. The technology was ... at the University of Cambridge., "The ...
... Vice President of Finance -, HOPKINTON, Mass., April ... ) today announced the promotion of Peter F.,McAree to ... as Vice President of Finance at Caliper. Effective April,4, ... CFO., McAree has more than 20 years of ...
... Chairman and CEO Honors the Anniversary by Ringing The Closing Bell(R) ... ... Calif., April 3, 2008 Edwards,Lifesciences Corporation (NYSE: EW ), ... today announced its,50th anniversary of partnering with clinicians to develop life-saving,innovations. ...
Cached Biology Technology:Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge 2Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge 3Caliper Life Sciences Appoints Peter F. McAree Senior Vice President and Chief Financial Officer 2Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations 2Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations 3
(Date:7/25/2014)... factor characterized by the existence of numerous isoforms ... to the protein deeply different characteristics. NRG1 plays ... during development and the different phases occurring after ... regrowth, remyelination and target reinnervation, Researchers at the ... soluble NRG1 upregulation observed in Schwann cells immediately ...
(Date:7/25/2014)... PITTSBURGH -- The routine use of a molecular ... likelihood of performing the correct initial surgery for ... from the University of Pittsburgh Cancer Institute (UPCI), ... the UPMC/UPCI Multidisciplinary Thyroid Center and other diagnostic ... the correct initial surgery by 30 percent, according ...
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... DALLAS May 20, 2008 Mutations in two ... the brain involved in sleep create a human-like insomnia ... found. The findings may help scientists better understand the ... This is one of the most dramatic ...
... exposure to chemicals is on the increase. From food ... with potentially-toxic substances could be affecting our health ... Nottingham are set to take part in one of ... on female mammals. Part of the Reproductive Effects of ...
... CITY Researchers have been unable to build an ... dream of ultrafast optical computers. But now, University of ... photonic crystals with the ideal, diamond-like structure: They are ... beetle from Brazil. It appears that a simple ...
Cached Biology News:Gene mutations in mice mimic human-like sleep disorder, UT Southwestern researchers find 2Do chemicals in the environment affect fertility? 2The photonic beetle 2The photonic beetle 3The photonic beetle 4The photonic beetle 5
... Rabbit polyclonal antibody to human XAB2 ... was first identified through its interaction with ... a fraction of XAB2 interacts with the ... well as with RNA polymerase II. Microinjection ...
... provide custom microplate coating using advanced automated high throughput microplate ... formats. We can also accommodate virtually any lot size of ... , 8 and 12 ... 384 well microplate, ...
...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: